Brinzolamide/Travoprost

布林佐胺/曲伏前列素

Report date: 2022/11/25 16:34:12

Base Information

Drug NameBrinzolamide/Travoprost
Drug Alias NameTravoprost+Brinzolamide曲伏前列素+布林佐胺布林佐胺+曲伏前列素Brinzolamide+Travoprost曲伏前列素/布林佐胺 +[6] 
ClassificationSmall molecules
Mechanisms of ActionProstanoid FP receptor agonistsCarbonic anhydrase II inhibitors
TargetsProstanoid FP receptorCarbonic anhydrase II
Therapy Area/IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesMexico +[4] 
CombinationsYes TravoprostBrinzolamide
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesAlcon
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSA Alcon Couvreur NVAlcon Research LtdAlcon
Active IndicationsN/A
Inactive IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension

Other Information

ATC CodeN/A
Related LinksN/A